Cobra Biologics and Centre for Process Innovation collaborate to advance development of regenerative medicines
Cobra and CPI will develop in depth scientific and technical understanding to allow a scalable and flexible manufacturing process to be developed to produce, purify and characterise a range of AAV vectors.
Cobra Biologics and the Centre for Process Innovation (CPI) are collaborating on a project which will focus on the development of an industrial manufacturing platform for Adeno-Associated Virus (AAV) production to support gene therapy and regenerative medicine. The £1.8M project, which is being led by Cobra, is being funded to a value of £1.4M by Innovate UK via their 2015 competition for the development of regenerative medicines and cell therapies.
The project is one of five which together comprise an £8 million investment into collaborative R&D projects that address critical challenges faced by UK companies developing regenerative medicines and cell therapies as clinical treatments and commercial products.
The collaboration between Cobra and CPI will focus on AAV vectors which are safe and effective, and are currently the delivery vehicle of choice for gene therapy treatments. However the advancement of these therapies into clinical trials is currently hampered by the lack of robust scalability needed to manufacture AAV vectors.
The proposed collaboration between Cobra and CPI will develop in depth scientific and technical understanding to allow a scalable and flexible manufacturing process to be developed to produce, purify and characterise a range of AAV vectors. This will enable the acceleration of more potential products into clinical testing and ultimately new medicines. This in turn will increase the chances of treatments being developed for a whole range of currently intractable diseases.
Peter Coleman, CEO Cobra Biologics commented: “Cobra has been a leading organisation in the development of the gene therapy sector for over 15 years now through its plasmid DNA and viral service offerings. We have seen through our customers an extraordinary growth in new potential medicines being put forward that utilise viral vectors as part of their production, such as Chimeric Antigen Receptor (CAR) T-Cell therapies. The collaboration between Cobra and CPI will help to address the need for a scalable AAV production process to meet the current and future needs of the gene therapy and regenerative medicine community in clinical trials and commercial supply.”
Dr Fergal O’Brien, Director of Biologics at CPI said: “CPI is delighted to be collaborating with Cobra Biologics Ltd and applying our expertise in developing scalable and industrial manufacturing platforms to AAV production. We see this project as a key enabler in meeting the current and future needs of the biologics industry and are delighted to be supporting a leading UK company in this sector.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance